Circulating Glutamine and Alzheimer's Disease: A Mendelian Randomization Study

Area of Science:

• Neuroscience
• Metabolic Research
• Genetics

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a global prevalence of over 24 million cases.
• The incidence of AD is projected to double by 2040, highlighting the urgent need for preventative strategies.
• Cognitive decline associated with AD poses a significant public health challenge.

Purpose of the Study:

• To investigate the potential neuroprotective role of circulating glutamine in Alzheimer's disease.
• To explore the relationship between glutamine levels and Alzheimer's disease risk using a genetic approach.

Main Methods:

• A two-sample Mendelian randomization study was conducted.
• Circulating glutamine levels were used as an instrumental variable.
• The study leveraged genetic variants associated with glutamine levels to infer causality.

Main Results:

• A statistically significant protective effect of higher circulating glutamine against Alzheimer's disease was observed (OR=0.83, P=0.02).
• Each standard deviation increase in circulating glutamine was associated with a reduced odds of developing Alzheimer's disease.
• The inverse-variance weighted method confirmed the association.

Conclusions:

• Findings support the hypothesis that glutamine/glutamate metabolism is modifiable and may play a role in preventing cognitive decline.
• Elevated glutamine may act as a neuroprotectant by providing substrate during times of neurological stress.
• Future research could explore exogenous glutamine modifications for Alzheimer's disease prevention and treatment.